

Special Report on Employer Management of High Cost Therapies (October 2024)




The *Special Report on Employer Management of High Cost Therapies* will examine employer readiness and strategies to proactively control spend attributed to expensive yet life-changing therapies. As fiduciary responsibility comes under the microscope, employers are challenged with maintaining affordable healthcare for all employees. Biopharmaceutical manufacturers can leverage this report to better understand employer decision making and plan design to effectively position their value proposition.

Report Topics:

- Influencers of benefit design and management strategies for high cost therapies
- PBM role and contracting dynamics
- Definition, identification and tracking of high cost therapy claims
- Value assessment, including ROI and VOI (value of investment)
- Approach to cell & gene therapy, rare diseases, oncology and related biomarker testing coverage and management strategies
- Familiarity and perspectives on payment models for high cost therapies
- Usage of Centers of Excellence
- Implications and opportunities for biopharmaceutical manufacturers

Top 5 Focus Area for Medication-Related Benefit Decisions:



n=109 Employers

Source: 2023 Employer Market Trends Report

A purchase includes:

- » Unlimited organization-wide access
- » Executive summary, implications and recommendations for manufacturers
- » One customized presentation and electronic copies of presentations for internal use
- » Access to Benfield Research website including downloading of deliverables
- » Inquiry privileges with employer market experts

Contact [Cristin Levine](#) at 314-656-2387 for additional purchasing details.